Integer (ITGR) vs LivaNova (LIVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LivaNova (LIVN) has outperformed Integer (ITGR) over the past year, gaining 42.2% versus a gain of 20.2%. Over five years, ITGR leads with a +41.9% price change compared with -9.5% for LIVN. Integer is the larger company by market cap ($4.31 billion vs $4.20 billion), about 1.0 times the size, while LivaNova is growing revenue faster (+10.7% vs +8.0%).
On valuation, LivaNova trades at a lower forward P/E (16.3x vs 18.4x for Integer). Integer converts more of its revenue into profit, with a net margin of 5.5% versus -17.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ITGR | LIVN |
|---|---|---|
| Share price | $126.65 | $76.52 |
| Market cap | $4.31B | $4.20B |
| 1-day change | 0.00% | +0.80% |
| YTD return | +61.48% | +23.37% |
| 1-year return | +20.21% | +42.23% |
| 5-year return | +41.86% | -9.51% |
| P/E ratio (TTM) | 34.60 | 22.64 |
| Forward P/E | 18.44 | 16.34 |
| EPS (TTM) | $3.66 | $3.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.85B | $1.39B |
| Revenue growth (YoY) | +7.98% | +10.74% |
| Net income (latest FY) | $102.81M | $-242.47M |
| Gross margin | 26.99% | 67.71% |
| Operating margin | 11.94% | 14.36% |
| Net margin | 5.55% | -17.47% |
| 52-week high | $126.80 | $85.76 |
| 52-week low | $62.00 | $48.82 |
| Distance from 52-week high | -0.12% | -10.77% |
| Analyst consensus | none | buy |
| Avg. price target upside | -3.83% | +18.34% |
| Average volume | 993.05K | 645.31K |
| Shares outstanding | 34.00M | 54.93M |
| Employees | 11,000 | 3,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LIVN has outperformed ITGR by 22.0 percentage points over the past year.
- Integer trades at a higher earnings multiple (34.6x vs 22.6x trailing P/E).
- Integer is more profitable, keeping 5.5 cents of every revenue dollar as net income versus -17.5 cents for LivaNova.
About Integer
ITGR stock →Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 11,000 employees
About LivaNova
LIVN stock →LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 3,300 employees
ITGR vs LIVN FAQ
Which is bigger, Integer or LivaNova?
Integer (ITGR) is larger, with a market capitalization of $4.31B compared with $4.20B for LivaNova (LIVN).
Which stock has performed better over the past year, ITGR or LIVN?
LIVN returned +42.23% over the past 12 months, compared with +20.21% for ITGR (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ITGR or LIVN?
LIVN has the lower trailing P/E at 22.6, versus 34.6 for ITGR. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Integer and LivaNova in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.